| Rank |
Title |
Year |
PubWeight™‹?› |
|
51
|
Antiretroviral gels: facing the FACTS.
|
2015
|
1.45
|
|
52
|
HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.
|
2015
|
1.45
|
|
53
|
Associations between HIV and schizophrenia and their effect on HIV treatment outcomes: a nationwide population-based cohort study in Denmark.
|
2015
|
1.44
|
|
54
|
Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland.
|
2015
|
1.44
|
|
55
|
Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial.
|
2014
|
1.43
|
|
56
|
PrEP: why are we waiting?
|
2015
|
1.43
|
|
57
|
Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis.
|
2015
|
1.43
|
|
58
|
Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study.
|
2014
|
1.42
|
|
59
|
Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis.
|
2015
|
1.42
|
|
60
|
Outcomes after viral load rebound on fi rst-line antiretroviraltreatment in children with HIV in the UK and Ireland:an observational cohort study.
|
2015
|
1.42
|
|
61
|
Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study.
|
2015
|
1.42
|
|
62
|
Pregnancy outcomes in HIV-positive women in Ukraine, 2000-12 (European Collaborative Study in EuroCoord): an observational cohort study.
|
2015
|
1.42
|
|
63
|
Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.
|
2016
|
1.42
|
|
64
|
Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study.
|
2015
|
1.41
|
|
65
|
Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study.
|
2015
|
1.40
|
|
66
|
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.
|
2015
|
1.40
|
|
67
|
End of AIDS on the horizon, but innovation needed to end HIV.
|
2015
|
1.40
|
|
68
|
Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study.
|
2015
|
1.38
|
|
69
|
Understanding the HIV disparities between black and white men who have sex with men in the USA using the HIV care continuum: a modeling study.
|
2014
|
1.37
|
|
70
|
How achievable is immediate ART for all?
|
2015
|
1.36
|
|
71
|
Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis.
|
2014
|
1.34
|
|
72
|
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
|
2015
|
1.31
|
|
73
|
Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk.
|
2015
|
1.21
|
|
74
|
Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey.
|
2016
|
1.20
|
|
75
|
The HOPE social media intervention for global HIV prevention in Peru: a cluster randomised controlled trial.
|
2015
|
1.13
|
|
76
|
Co-trimoxazole in people on antiretroviral therapy for HIV.
|
2015
|
1.08
|
|
77
|
The importance of replicating results from randomised trials.
|
2016
|
1.07
|
|
78
|
Promoting male partner HIV testing and safer sexual decision making through secondary distribution of self-tests by HIV-negative female sex workers and women receiving antenatal and post-partum care in Kenya: a cohort study.
|
2016
|
0.98
|
|
79
|
Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.
|
2014
|
0.97
|
|
80
|
Light and shade behind the opt-out system for the HIV screening.
|
2015
|
0.96
|
|
81
|
Light and shade behind the opt-out system for the HIV screening.
|
2015
|
0.96
|
|
82
|
Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk.
|
2015
|
0.94
|
|
83
|
Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk.
|
2015
|
0.93
|
|
84
|
Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
|
2016
|
0.93
|
|
85
|
Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study.
|
2014
|
0.92
|
|
86
|
HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study.
|
2014
|
0.92
|
|
87
|
National sex work policy and HIV prevalence among sex workers: an ecological regression analysis of 27 European countries.
|
2017
|
0.91
|
|
88
|
Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial.
|
2014
|
0.91
|
|
89
|
90-90-90: how do we get there?
|
2014
|
0.90
|
|
90
|
Assisted partner services for HIV in Kenya: a cluster randomised controlled trial.
|
2016
|
0.89
|
|
91
|
Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial.
|
2016
|
0.88
|
|
92
|
Nurse-led palliative care for HIV-positive patients taking antiretroviral therapy in Kenya: a randomised controlled trial.
|
2015
|
0.88
|
|
93
|
Churning in and out of HIV care.
|
2014
|
0.87
|
|
94
|
Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.
|
2015
|
0.87
|
|
95
|
HIV Prevention 2020: a framework for delivery and a call for action.
|
2016
|
0.86
|
|
96
|
Group support psychotherapy for depression treatment in people with HIV/AIDS in northern Uganda: a single-centre randomised controlled trial.
|
2015
|
0.86
|
|
97
|
Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study.
|
2016
|
0.86
|
|
98
|
The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring.
|
2016
|
0.85
|
|
99
|
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
|
2017
|
0.85
|
|
100
|
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study.
|
2014
|
0.85
|